VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE
LARGE B-CELL LYMPHOMA OUTCOME PREDICTION

J 2005

VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION

SVOBODA, Marek, Jitka BERKOVCOVÁ, Pavel FABIAN, Ingrid VÁŠOVÁ, Dana DVOŘÁKOVÁ et. al.

Basic information

Original name

VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION

Name in Czech

Validace vybraných izoforem proteinkinasy C pro predikci vývoje difúzního velkobuněčného B-lymfomu.

Authors

SVOBODA, Marek (203 Czech Republic, guarantor), Jitka BERKOVCOVÁ (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Ingrid VÁŠOVÁ (203 Czech Republic) and Dana DVOŘÁKOVÁ (203 Czech Republic)

Edition

Annals of Oncology, European Society for Medical Oncology, 2005, 0923-7534

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.319

Organization unit

Faculty of Medicine

UT WoS

000233670100465

Keywords in English

Lymphoma; protein kinase C; prediction

Abstract

ORIG CZ

V originále

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkins lymphoma, characterized by its clinical heterogenity. Global gene expression profiling subdivide the DLBCL into two main clinically and biologically distinct subgroups. Gene expression signatures characteristic of particular subgroups include different isophorms of protein kinase C (PKCs). According microarrays analyses, the increased expression of PKC-delta (PKCD) and PKC-gamma (PKCG) is present in DLBCL with favourable prognosis, but PKC beta I (PKCBI) and II (PKCBII) is present in fatal or refractory DLBCL. Methods: We used Reverse-Transcription PCR (RT-PCR), Quantitative Real-Time PCR (QRT-PCR) and immunohistochemical (IHC) analyses to validate the expression of selected PKCs isophorms in formalin fixed and paraffin embed (FFPE) tumor specimens from 52 patients treated for DLBCL between 1996 and 2003. Results: 1) We developed modified technique for RNA isolation from FFPE tumor specimens producing RNA of sufficient quantity and suitable quality for RT-PCR and QRT-PCR. 2) Using the IHC, RT-PCR, QRTPCR and DNA sequenation we confirmed that B-lymphocytes do not express PKCG. 3) We found that DLBCL patients, who achieved complete or partial remission after the first course of chemotherapy, and patients remained alive at 20-month follow-up, express low level of PKCD mRNA (P = 0.0089 and P = 0.0064 respectively). Conclusions: Data from microarray analyses need to be interpreted cautiously. PKCD seems to be potential predictive and prognostic marker in DLBCL.

In Czech

Publikace pouze v anglickém jazyce

Citovat

SVOBODA, Marek, Jitka BERKOVCOVÁ, Pavel FABIAN, Ingrid VÁŠOVÁ and Dana DVOŘÁKOVÁ. VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION. Annals of Oncology. European Society for Medical Oncology, 2005, vol. 2005, Suppl5, p. 173. ISSN 0923-7534.

@article{726205,
   author = {Svoboda, Marek and Berkovcová, Jitka and Fabian, Pavel and Vášová, Ingrid and Dvořáková, Dana},
   article_number = {Suppl5},
   keywords = {Lymphoma; protein kinase C; prediction},
   language = {eng},
   issn = {0923-7534},
   journal = {Annals of Oncology},
   title = {VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION},
   volume = {2005},
   year = {2005}
}

TY  - JOUR
ID  - 726205
AU  - Svoboda, Marek - Berkovcová, Jitka - Fabian, Pavel - Vášová, Ingrid - Dvořáková, Dana
PY  - 2005
TI  - VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION
JF  - Annals of Oncology
VL  - 2005
IS  - Suppl5
SP  - 173
EP  - 173
PB  - European Society for Medical Oncology
SN  - 09237534
KW  - Lymphoma
KW  - protein kinase C
KW  - prediction
N2  - Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkins lymphoma, characterized by its clinical heterogenity. Global gene expression profiling subdivide the DLBCL into two main clinically and biologically distinct subgroups. Gene expression signatures characteristic of particular subgroups include different isophorms of protein kinase C (PKCs). According microarrays analyses, the increased expression of PKC-delta (PKCD) and PKC-gamma (PKCG) is present in DLBCL with favourable prognosis, but PKC beta I (PKCBI) and II (PKCBII) is present in fatal or refractory DLBCL. Methods: We used Reverse-Transcription PCR (RT-PCR), Quantitative Real-Time PCR (QRT-PCR) and immunohistochemical (IHC) analyses to validate the expression of selected PKCs isophorms in formalin fixed and paraffin embed (FFPE) tumor specimens from 52 patients treated for DLBCL between 1996 and 2003. Results: 1) We developed modified technique for RNA isolation from FFPE tumor specimens producing RNA of sufficient quantity and suitable quality for RT-PCR and QRT-PCR. 2) Using the IHC, RT-PCR, QRTPCR and DNA sequenation we confirmed that B-lymphocytes do not express PKCG. 3) We found that DLBCL patients, who achieved complete or partial remission after the first course of chemotherapy, and patients remained alive at 20-month follow-up, express low level of PKCD mRNA (P = 0.0089 and P = 0.0064 respectively). Conclusions: Data from microarray analyses need to be interpreted cautiously. PKCD seems to be potential predictive and prognostic marker in DLBCL.
ER  -

SVOBODA, Marek, Jitka BERKOVCOVÁ, Pavel FABIAN, Ingrid VÁŠOVÁ and Dana DVOŘÁKOVÁ. VALIDATION OF SELECTED PROTEIN KINASE C ISOPHORMS FOR DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION. \textit{Annals of Oncology}. European Society for Medical Oncology, 2005, vol.~2005, Suppl5, p.~173. ISSN~0923-7534.

Detailed Information on Publication Record